Portal de Periódicos da CAPES

Pediatric Tuberculosis: Global Overview and Challenges

2010; Oxford University Press; Volume: 50; Issue: s3 Linguagem: Inglês

10.1086/651490

1537-6591

Soumya Swaminathan, Banu Rekha,

Pneumocystis jirovecii pneumonia detection and treatment

Tuberculosis (TB) is among the top 10 causes of death among children worldwide; however, ch are given low priority in most national health programs and are neglected in this epidemic.Re advancements in diagnosis of TB in adults have not been validated in children.Similarly, tria and development of pediatrie formulations of standard first-and second-line drugs are laggin human immunodeficiency virus (HlV)-coinfected children, the optimal timing for highly acti therapy initiation and drug combinations that have minimal interactions with anti-TB dru study.Although bacille Calmette-Guérin vaccine, the only vaccine available for TB, protects inated and severe forms of the disease in young children, its safety in the HIV-infected pop questioned.Multicentric trials are urgently required to help develop improved diagnostic str mulate shorter, more effective, safe, and evidence-based regimens for treatment and prev susceptible and drug-resistant TB.Worldwide, the burden of tuberculosis (TB) has been adversely influenced by the human immunodeficiency virus (HIV) epidemic and by social and economic factors that affect health care delivery.TB in children is a direct consequence of adult TB and is a good marker of current transmission in the community.Although advances have been made in diagnostics and new drugs for treatment of TB in adults, development in children has lagged behind.This review examines the current status of diagnosis, prevention, and treatment of TB in children and highlights knowledge gaps and research priorities for each of these topics.